Author: cadams
-
Andarix Pharmaceuticals CEO to Present on Building High-Value Biotechnology Companies at Outsourcing in Clinical Trials New England Conference
FOR IMMEDIATE RELEASE October 16, 2025 Contact:Andarix Pharmaceuticals617-957-9858info@andarix.com Presentation Highlights Essential Tools and Strategies for Successful Biotech Company Formation BOSTON, MA – October 16, 2025 – Andarix Pharmaceuticals, a clinical-stage biopharmaceutical company developing next-generation targeted radiotherapeutics for oncology, announced today that Chief Executive Officer Chris Adams will present on the essential tools and strategies needed…
-
Andarix Pharmaceuticals Advances Targeted Peptide Therapy Platform for Rare Cancers
CEO to Present at Major Industry Summit as Company Gains Momentum in Personalized Cancer Treatment BOSTON – July 23, 2025 – Andarix Pharmaceuticals, a clinical-stage biotechnology company pioneering targeted peptide therapies for rare cancers, today announced that CEO Chris Adams will present at the 3rd Targeted Radiopharmaceuticals Supply Chain & Manufacturing Summit in Boston on July 23-24, 2025.…
-
Andarix Pharmaceuticals CEO to Present on Targeted Radiometal Therapeutics for Lung Cancer at International Symposium on Bioorganometallic Chemistry 2025
Presentation underscores Andarix’s leadership in advancing radiometal-based cancer therapeutics and highlights partnering and investment opportunities in a rapidly growing field. FOR IMMEDIATE RELEASE August 25, 2025 Contact: Andarix Pharmaceuticals 617-957-9858 info@andarix.com Boston, MA – August 25, 2025 – Andarix Pharmaceuticals, a clinical‑stage biopharmaceutical company developing next‑generation targeted radiotherapeutics for oncology, today announced that Chief Executive Officer Chris…
-
Pioneering Targeted Therapies: Andarix Presents New Data on Radiopharmaceutical Innovations for Lung and Pancreatic Cancer
FOR IMMEDIATE RELEASE July 29, 2025 Contact: Andarix Pharmaceuticals 617-957-9858 info@andarix.com Driving New Partnerships and Investment Opportunities in Precision Oncology Radiopharmaceuticals Boston — At the 4th Targeted Radiopharmaceuticals Summit US, Andarix Pharmaceuticals is showcasing its pioneering targeted radiopharmaceutical technology for treating lung and pancreatic cancer. Company leadership is presenting recent data demonstrating how Andarix’s proprietary…
-
Andarix Pharmaceuticals CEO to Highlight Advances in Cancer Clinical Trials at Industry Conference
July 8, 2025 Contact:Andarix Pharmaceuticals617-957-9858info@andarix.com Targeted Peptide Therapy and Pioneering Cancer Clinical Trials Featured at Upcoming Event Boston, MA — Andarix Pharmaceuticals, a leader in the discovery and development of targeted peptide therapies for rare cancers, announced today that CEO Chris Adams will deliver a keynote presentation at the Clinical Trials in Oncology Conference, taking…
-
Andarix Pharmaceuticals CEO to Chair Radiopharmaceutical Conference
February 26, 2025 Targeted Radiotherapies: A New Approach to Treating Cancer Boston — ANDARIX Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for rare cancers, announced today that its CEO, Chris Adams, will chair a session at the targeted therapy conference in Boston. The conference will include attendees from industry experts…
-
Andarix Pharmaceuticals CEO to Groundbreaking Targeted Peptide Therapy at Clinical Trials Conference
October 23, 2024 Innovative Approach to Rare Cancer Treatment Attracts Attention from Industry Leaders and Patient Groups Boston — Andarix Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for rare cancers, announced today that its CEO, Chris Adams will present the two-day conference on outsourcing clinical trials. The conference will include…
-
Andarix Pharmaceuticals CEO to Chair Rare Disease Clinical Trials Conference
September, 2023 Andarix Pharmaceuticals CEO to Chair Rare Disease Clinical Trials Conference Boston — Andarix Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for rare cancers announced today that its CEO, Chris Adams will Chair the two days conference on rare diseases. The conference will include attendees from industry experts to…
-
Andarix Pharmaceuticals to Lead Panel Discussion at Clinical Trial Conference
July 11, 2023 Conference Highlights Key Features of Successful Clinical Trial Management SOMERVILLE, MA — July 11, 2023 — Andarix Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for cancer announced today that it will lead a panel discussion composed of industry experts on the key components of clinical trial management…
-
Andarix Pharmaceuticals to Participate in Life Science Panel of Biotech and MedTech Entrepreneurs at Life Science Summit 22
November 2, 2022 Personalized and targeted medicine for lung and other cancers SOMERVILLE, MA —November 2, 2022— Andarix Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for cancer announced today that it will participate on a panel discussion of biotech company formation and management experiences. The panel will be part of…